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Abstract Recent cloning of the cDNA for Fas/Apo-1 and its 
ligand has revealed that they belong to the tumor necrosis factor 
(TNF) receptor and TNF family, respectively, and play an impor- 
tant role in apoptosis (programmed cell death). Like TNF, anti- 
bodies against the Fas antigen (anti-Fas) have been shown to be 
cytotoxic to Fas-expressing cells. Whether Fas, like TNF recep- 
tor, also mediates proliferation of normal human diploid fibro- 
blasts (HDF), is not known. In this study, we show that HDF 
expresses Fas antigen and the engagement of this antigen signals 
proliferation of these cells in a dose-dependent manner. Unlike 
TNF receptor, however, Fas-mediated proliferation of HDF 
could not be blocked by orthovanadate, a tyrosine phosphatase 
inhibitor. The difference in the signaling was further evident from 
our observation that TNF induced the expression of interleukin-6 
but anti-Fas did not. Overall, our results demonstrate for the first 
time that besides cell killing, Fas also mediates proliferation of 
HDF and that its mechanism is different from that of TNF 
receptor. 
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1. Introduction 
Tumor necrosis factor (TNF) is a 26 kDa type II transmem- 
brane non-glycoprotein of 233 amino acid residues whose 17 
kDa extracellular domain (157 amino acids) is secreted by a 
number of different cell types, including activated macro- 
phages. TNF is cytotoxic to some tumor cells but stimulates the 
proliferation of other cell types (for references see [1]). It is also 
involved in a wide variety of other biological actions [1,2]. TNF 
interacts with cells through two distinct receptors, p60 and pS0, 
whose extracellular domains are highly homologous in amino 
acid sequence but whose cytoplasmic domains are quite distinct 
[3]. 
Another member has been added to the tumor necrosis fac- 
tor (TNF) receptor superfamily with the recent cloning of the 
cDNA for human Fas/Apo-1 antigen (Fas), which revealed that 
it is a transmembrane 319 amino acid polypeptide with a molec- 
ular mass of 36 kDa [4]. The isolation of the ligand that inter- 
acts with human Fas has shown that it is a type II transmem- 
brane polypeptide of 278 amino acids with molecular mass of 
31 kDa and that it, too, is a member of the TNF family [5]. Its 
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putative xtracellular domain consists of 179 amino acids and 
contains four potential N-glycosylation sites [5]. The Fas anti- 
gen has been shown to be expressed by various human cells, 
including myeloid cells, T-lymphoblastoid cells, and diploid 
fibroblasts [6], whereas the Fas ligand is expressed by activated 
splenocytes, thymocytes, and certain non-lymphoid tissues 
such as testis [5]. 
By using human diploid fibroblast cells as an immunogen, 
Yonehara nd colleagues developed a Fas mAb, anti-Fas, that 
is cytolytic to Fas-expressing cells [6]. Since the Fas antigen and 
TNF receptor were co-down-regulated, it was suggested that 
the Fas antigen may be associated with the TNF receptor. A 
similar antibody called Apo-I has been described that also 
recognizes Fas [7]. Although the extracellular domain of the 
p60 form of TNF receptor displays as much amino acid se- 
quence homology (24~30%) to the Fas antigen as to the p80 
TNF receptor, their cytoplasmic domains are quite distinct. 
This has led to the hypothesis that p60, p80, and Fas must 
transduce distinct signals, even though all three receptors can 
mediate cell killing. A close examination of the cytoplasmic 
domain of the p60 receptor and Fas has led to the identification 
of a 45-amino acid region that displays 51% homology between 
the two [4]. Since the deletion of this domain in both the p60 
receptor and Fas abolished their ability to mediate cell killing, 
this domain has been referred to as the 'death domain' [8,9]. 
Besides cell killing, TNF receptors have been shown to medi- 
ate proliferation of normal human diploid fibroblast (HDF) 
[2,10], but whether Fas can also signal this activity is not 
known. To help resolve that question we compared TNF with 
anti-Fas. Our results indicate that Fas antigen, like TNF recep- 
tor, mediates proliferation of HDF but unlike TNF, the prolif- 
erative signal induced by Anti-Fas is insensitive to orthovana- 
date. Also, unlike TNF, we found that treatment of HDF with 
anti-Fas does not lead to IL-6 production. Our results uggest 
that the death domain present in both p60 and the Fas receptors 
must mediate not only cytotoxic but also proliferative signals. 
2. Materials and methods 
2.1. Materials 
RPMI-1640 was obtained from Whittaker MA Bioproducts (Walk- 
ersville, MD). Fetal bovine serum (FBS) and gentamicin were from 
Gibco (Grand Island, NY). Bacteria-derived r combinant human TNF 
(specific activity 5 × 10 v U/mg) was kindly supplied by Genentech Inc. 
(South San Francisco, CA). Anti-Fas was a generous gift from Dr. Shin 
Yonehara, The University of Kyoto (Kyoto, Japan). Other chemicals 
and biochemicals were obtained from Sigma Chemical Co. (St. Louis, 
MO). Human diploid fibroblasts (HDF) were kindly provided by Dr. 
Olivia Perreira-Smith (Baylor College of Medicine, Houston, TX). 
Cells were routinely grown in RPMI 1640 medium supplemented with 
glutamine (2 mM), gentamicin (50 /.tg/ml), and fetal bovine serum 
(lO%). 
All rights reserved. 
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2.2. Expression ofFas antigen, p60, and p80 receptor byflow cytometrv 
Expression of Fas antigen was determined by using Anti-Fas mAb 
as described by Yonehara et al. [6]. Briefly, 0.2 x 10 6 cells were incu- 
bated with 1 ,ug of anti-Fas in a final volume of 50/A PBS containing 
5% FBS and 0.01% sodium azide for 1 h on ice. After two washes with 
ice-cold PBS containing 5% FCS and 0.01% NAN3, 10 pg/ml of fluores- 
cein-conjugated affinity purified F(ab)2 fragment goat anti-mouse IgM 
(Capple, Organon Tekemika, West Chester, PA) were added in a final 
volume of 50/11 and incubated on ice for an additional 1h. Cells were 
washed twice and resuspended in PBS containing 1% paraformalde- 
hyde. Cells stained by second antibody alone were used to determine 
background fluorescence. Expression of p60 and p80 was determined 
by using htr-9 and utr-1 [8] respectively, at a concentration f 20/tg/ml 
followed by staining with second antibody (FITC-conjugated goat 
F(ab)'2 anti-mouse IgG (H + L) (Caltag, San Francisco, CA). FITC 
fluorescence was detected on a log scale using a FACScan analyzer 
(Becton-Dickinson, Mountain View, CA). 
2.3. Fibroblast proliferation assays 
Cell growth-stimulatory assays were carried out essentially according 
to the procedure described by Vilcek et al. [10]. Briefly, confluent 
human diploid foreskin fibroblasts (at passage level 12-15) were used 
for cell growth-stimulatory assays. To determine the effect of TNF and 
anti-Fas, cells (8x 103/well) were plated in 0.1 ml of the medium 
(RPMI-1640 + 10% FBS) in 96-well Falcon plates. After overnight 
incubation in a CO2 incubator at 37°C, the medium was removed and 
a serial dilution of the TNF or anti-Fas was layered in 0.1 ml of 
RPMI-1640 medium. During the last 24 h of a 72 h incubation, tritiated 
thymidine (6.7 Ci/mmol) was added to each well (0.5 HCi/well). The 
culture medium was then removed, the wells were washed twice with 
PBS, the cells suspension was harvested with the aid of a Packard 
Micromate 196 cell harvester onto a glass fiber filter, and radioactivity 
bound to the filter was measured in a Packard Matrix 9600 direct beta 
counter (Packard Co., Meriden, CT). Relative cell viability was calcu- 
lated as the amount of thymidine incorporated in treated cells divided 
by that in the untreated cells and expressed as a percentage. The cell 
proliferation obtained with thymidine incorporation was found to cor- 
relate with cell number monitored by Trypan blue exclusion as well as 
by the Crystal violet dye uptake method. Although for most experi- 
ments confluent cell cultures (8 × 103 cells/well) were used, subconfluent 
cultures (4 x 103 cells/well) also gave similar results. 
2.4. Determination f &terleukin-6 
HDF at 0.1 × l06 cells/ml were incubated in 24-well plates with TNF 
(20 ng/ml) or anti-Fas (20 ng/ml) for 24 h, and then the supernatants 
were collected. The presence of IL-6 was determined by using the 
IL-6-dependent murine B cell hybridoma B-9 as described previously 
[11]. Briefly, 2 x 103 cells were incubated in 0.2 ml of RPMI-1640 con- 
taining 10% FBS in 96-well plates with different concentrations of
either IL-6 or IL-6-containing supernatants for 96 h, and then during 
the last 6 h, cells were pulsed with 0.5/ICi of tritiated thymidine and 
harvested, and cell-associated radioactivity counted as described for the 
cell proliferation assay. Half-maximal thymidine incorporation was 
considered as one unit and this was obtained with 1 pg of IL-6. 
3. Results 
3.1. Human fibroblast express Fas on the cell surjace 
Immunofluorescent analysis with specific monoclonal  anti- 
bodies showed that Fas was expressed by normal fibroblasts 
(Fig. 1). These cells also expressed mainly p60 but very little p80 
forms of the TNF  receptors. 
3,2. Fas antigen mediates prohferation of fibroblasts 
Since TNF  induces the proliferation of normal human fore- 
skin diploid fibroblasts, we examined the effect of anti-Fas on 
these cells. The results shown in Fig. 2 indicate that, like TNF, 
anti -Fas induced the proliferation of fibroblasts in a dose-de- 
pendent manner. The effect of TNF  appeared at concentrations 
as low as 0.1 ng/ml, whereas for anti-Fas, 10 ng/ml was 
required. Thus, the Fas antigen, like the TNF  receptor, medi- 
ates not only cell killing but also cell proliferation. The prolifer- 
ation of cells occurred even in the absence of the serum, but the 
overall increase was 4-10 times lower than of cells cultured with 
serum. 
3.3. Fas-mediated fibroblast proliJeration occurs by a mechanism 
different J?om that of TNF 
Previously it has been reported that TNF- induced fibroblast 
proliferation can be completely blocked by orthovanadate,  an 
inhibitor of protein tyrosine phosphatase [12]. We investigated 
whether orthovanadate also blocks anti-Fas-mediated prolifer- 
ation of HDF. The results shown in Fig. 3 indicate that TNF-  
dependent proliferation was inhibited by orthovanadate but 
not that mediated through anti-Fas. This demonstrates that the 
mechanism of cell proliferation for anti-Fas differs from that 
of TNF. 
3.4. Fas does not mediate IL-6 expression in fibroblasts 
Since treatment of fibroblasts with TNF  leads to the expres- 
sion of IL-6, we examined the ability o fant i -Fas  to induce IL-6. 
Human fibroblasts were treated with 200 ng/rnl of either TNF  
or anti-Fas for 24 h, and then the supernatants were assayed 
for IL-6 activity by bioassay. The results in Fig. 4 indicate that 
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Fig. 1. Both Fas and TNF receptors are expressed on the surface of 
human fibroblasts. Cells (0.2 x 106/0.05 ml) were incubated with mcAb 
anti-Fas or anti-p60 (htr-9) or anti-p80 (utr-l) for 1 h on ice. After two 
washes, cells were incubated for an additional 1 h with fluorescein- 
conjugated goat anti-mouse IgM (for Fas) or goat anti-mouse IgG (for 
p60 and p80). Cells were washed, fixed and analyzed for fluorescence 
on a FACScan analyzer. Cells were stained by second antibody alone 
to determine background fluorescence. Unstained cells are shown as 
solid lines, cells stained with second antibody alone are dotted lines and 
those stained with first and second antibody are shown as shadded area. 
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Fig. 2. Anti-Fas and TNF induces dose-dependent proliferation of 
normal diploid fibroblasts. Cells (8 × 103 in 0.1 ml) in 96-well plates 
were incubated with different concentrations of anti-Fas and TNF at 
37°C for 72 h, and thereafter cell proliferation was determined by 
tritiated thymidine incorporation asdescribed in section 2. All determi- 
nations were made in triplicate. The total mean cpm incorporation i
the untreated control was 1196 (at 100% relative cell viability). 
TNF  was a potent inducer of IL-6 whereas anti-Fas has no 
effect. Thus even though HDF undergoes similar proliferative 
responses to both anti-Fas and TNF, their effect on IL-6 ex- 
pression differs substantially. 
4. Discussion 
Both TNF  and TNF receptor are structurally homologous 
to the Fas ligand and the Fas antigen, respectively. Whether 
Fas ligand (anti-Fas) and TNF have similar properties, how- 
ever, is not known. In the present report we demonstrate hat, 
like TNF, anti-Fas was found to induce the proliferation of 
normal human diploid fibroblasts, but by a mechanism differ- 
ent from that of TNF. Our results also show that, unlike TNF, 
anti-Fas did not induce the expression of interleukin-6. 
Anti-Fas is a mAb that was made by immunizing mice with 
normal human diploid fibroblasts [6]. It was found to recognize 
a cell surface molecule, termed Fas, on different cell types and 
to induce cytotoxicity that could not be distinguished from that 
induced by TNF. 
We found that anti-Fas does not just kill all the Fas-express- 
ing cells; it also induces proliferation of normal fibroblasts. In 
this respect, anti-Fas displays a property similar to TNF. The 
proliferative ffects of TNF  on fibroblasts has been shown to 
be mediated through the p60 form of the TNF  receptor [13] 
whose cytoplasmic domain exhibits homology to that of Fas. 
There has been no previous report of growth-stimulation by
anti-Fas alone on normal cells but it has been shown that 
anti-Fas co-stimulates the proliferation of purified human T 
cells and thymocytes in the presence ofanti-CD3 [14]. Interest- 
ingly, although both TNF  and anti-Fas timulated the prolifer- 
ation of fibroblast, anti-Fas did not induce the expression of 
IL-6 in these cells but TNF  did. Why anti-Fas would induce 
proliferation but not IL-6 expression is not clear, but there is 
clearly a difference in signaling between TNF  and anti-Fas. 
This difference is further evident from our results that TNF-  
dependent proliferation of fibroblasts involves an orthovana- 
date-sensitive protein tyrosine phosphatase but not that medi- 
ated through anti-Fas. 
It is not clear why TNF induces IL-6 expression i  fibroblasts 
but anti-Fas does not. When TNF interacts with its receptor, 
one of the earliest events is the activation of a nuclear transcrip- 
tional factor, NF-lcB, which could be observed within 5 rain 
[15]. This activation leads to the induction of various genes 
including IL-6 [16]. In contrast, we found that interaction of 
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Fig. 3. Effect of orthovanadate onthe anti-Fas- and TNF-dependent 
proliferation of normal diploid fibroblasts. Cells (8 x 103 in 0.1 ml) in 
96-well plates were incubated with 100 ng/ml of either anti-Fas or TNF 
or orthovanadate (1 pg/ml) or indicated combinations at 37°C for 72 h. 
Thereafter cell proliferation was determined by tritiated thymidine in- 
corporation as described in section 2. Results are based on proliferation 
of cells with media alone as 100%. All determinations were made in 
triplicate. 
8 B.B. Aggarwal et al./FEBS Letters 364 (1995) 5~8 
120. 
10o. 
80. 
'9 
4o. 
20 
0 ~  
None TNF  ant i -Fas  
Fig. 4. Induction of expression of IL-6 by TNF and anti-Fas in fibro- 
blast cells. 0.1 × 10 6 cells (1 ml) were incubated with TNF (200 ng/ml) 
or anti-Fas (200 ng/ml) at 37°C for 24 h and then cell supernatants were 
harvested for IL-6 determination bybioassay as described in section 2. 
All determinations were made in duplicate. 
anti-Fas with its cell surface receptor did not activate NF-tcB 
(data not shown), perhaps explaining why IL-6 expression was 
not induced by anti-Fas. The difference in the signaling of the 
p60 form of the TNF  receptor and Fas has been reported 
previously [17]. Thus, overall our results indicate that anti-Fas 
exhibits not only cytotoxic but also growth-stimulatory effects 
that are similar to those of TNF, but the pattern ofgene activa- 
tion and its expression is quite different. The signals mediated 
through Fas and TNF  receptor also seem to be independent of 
each other. 
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